Your team is weighing polymer candidates for a long-acting injectable, and procurement needs a defensible comparison before locking a specification. PLGA and PLA are usually first on the shortlist because both are biodegradable, cleared for clinical use, and proven in marketed products. They are not interchangeable, however: the two polymers differ in degradation rate, release kinetics, and the clinical scenarios they fit. This guide compares the two so you can match the polymer to the program.
Why Biodegradable Polymers Are Used in Drug Delivery
Biodegradable polymers earn their place in drug delivery for three practical reasons. Controlled release: a single dose can deliver a therapeutic over weeks or months instead of requiring daily administration. Reduced dosing frequency: fewer injections improve adherence and lighten the load on patients and caregivers. Targeted therapy: local delivery concentrates the drug at the disease site, which can lower systemic exposure and side effects. Because these polymers hydrolyze into metabolites cleared through normal pathways, no removal procedure is needed once the drug is exhausted.
What Is PLGA?
PLGA, or poly(lactic-co-glycolic acid), is a copolymer of lactic acid and glycolic acid. Its defining feature is tunability: by adjusting the lactide-to-glycolide ratio and molecular weight, formulators can shift degradation from a few weeks to several months. PLGA also has a long regulatory record. Lupron Depot (leuprolide acetate) and Zoladex (goserelin) are among the established products built on PLGA-based systems, giving procurement teams a familiar precedent for audits and supplier qualification.
What Is PLA?
PLA, or polylactic acid, is the homopolymer of lactic acid. With no glycolide comonomer, it is more crystalline and more hydrophobic, which slows water uptake and hydrolysis. The practical result is a slower, steadier degradation profile that can extend release beyond what most PLGA formulations achieve. PLA is widely specified in resorbable implants, sutures, and long-acting devices, and its behavior in healthcare settings is well documented in our guide to polylactic acid in medicine.
Degradation and Release Kinetics
In general terms, PLGA degrades faster and is more adjustable. Higher glycolide content accelerates hydrolysis, while higher lactide content or molecular weight slows it, so release can be engineered from roughly two weeks to several months. PLA degrades more slowly, with devices commonly designed for multi-month release. Both polymers break down by hydrolysis of ester bonds into lactic and glycolic acid, which enter normal metabolic pathways. The kinetics of PLGA-based carriers are characterized extensively in the literature, notably by Makadia and Siegel.
Applications in Drug Delivery Systems
PLGA microparticles and nanoparticles are a workhorse for peptides and proteins, protecting the payload and controlling its release; marketed products and extensive preclinical work support this role. PLA is more often specified for longer-acting implants and structural devices, where a slower, more crystalline matrix is an advantage. The broader biomedical use of biodegradable polymers — sutures, orthopedic devices, drug carriers — is surveyed by Ulery and colleagues.
Tradeoffs: Burst Release, Acidic Byproducts, and Onset
Each polymer carries compromises. PLGA has a burst-release risk, where a portion of the dose is released quickly after administration, and its acidic degradation byproducts can lower local pH in sensitive tissues. PLA offers a slower onset of release, which suits chronic conditions but can delay the achievement of therapeutic levels, and its lower tunability makes fine adjustments harder. Both materials hydrolyze, so storage, humidity control, and sterilization validation deserve equal attention either way.
| Property | PLGA | PLA |
|---|---|---|
| Composition | Copolymer of lactic acid and glycolic acid | Homopolymer of lactic acid |
| Degradation rate | Faster; tunable via glycolide ratio (roughly weeks to months) | Slower; more crystalline (multi-month profiles) |
| Release profile | Adjustable; burst-release risk to manage | Slow and steady; slower onset |
| Approved products | Lupron Depot, Zoladex (PLGA-based systems) | Resorbable implants, sutures, devices |
| Recommended use | Microparticles and nanoparticles for peptides and proteins | Longer-acting implants and structural devices |
Research and Procurement Outlook for 2026
Research remains strong on both fronts into 2026. Teams are refining PLGA formulations to reduce burst release, combining polymers to balance onset and duration, and validating long-acting injectables for chronic care. For procurement, the question is less about which polymer is inherently superior and more about which fits the drug, dosing interval, and target tissue.
When a program needs a fast, tunable carrier for a peptide or protein, PLGA is the established default. When the goal is a multi-month implant with slower, steadier release, PLA is often the more reliable choice. For more detail on how PLA behaves in real devices, see polylactic acid in medicine; for the mechanisms behind polymer-based release, our overview of PHA in drug delivery covers related chemistry from another angle.
Sources: Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel). 2011;3(3):1377-1397. PMC3972197 · Ulery BD, et al. Biomedical applications of biodegradable polymers. J Polym Sci B Polym Phys. 2011;49(12):832-864. PMID 21769165.
Facilities shifting toward greener purchasing often start with high-volume disposables. CliniEco offers PLA biodegradable underpads and PLA bed sheets as a practical, certified starting point for Canadian clinics and long-term care homes.
Related Reading
Explore more guides in this category:
- Quat vs Bleach vs Alcohol Wipes: Disinfectant Chemistry Explained
- Wound Dressing Basics: Gauze, ABD Pads & Bandages Explained
- ISO 11140-1 Explained: Chemical Indicator Classes for Sterilization
- compliance log generator
Related reading
Frequently Asked Questions
What is the main difference between PLGA and PLA?
PLGA is a copolymer of lactic acid and glycolic acid, and its lactide-to-glycolide ratio and molecular weight can be adjusted to shift degradation from a few weeks to several months. PLA is the homopolymer of lactic acid: more crystalline and more hydrophobic, so it takes up water more slowly and degrades more slowly.
Which polymer releases a drug faster?
PLGA generally releases faster and offers more control over the release window, which is why most marketed long-acting injectables are built on it. PLA hydrolyses more slowly, which supports longer release periods and suits resorbable implants and sutures.
Do both polymers have to be removed once the drug is exhausted?
No. Both hydrolyse into metabolites cleared through normal metabolic pathways, so no retrieval procedure is needed after the dose is spent. That is one reason both are specified for injectable and implantable systems.
What should procurement ask a supplier for?
The monomer ratio and molecular weight of the grade offered, the intended degradation window, residual monomer and solvent limits, and the documentation supporting use in a medical device, typically a materials evaluation prepared for the intended contact category.
Does one polymer suit every programme?
No. The selection follows the release profile the programme needs: PLGA where the target window is weeks to a few months and the formulation requires tuning, PLA where a slower and steadier release is the requirement.
CliniEco Medical is a licensed medical device establishment (MDEL #35334).
0 commentaire